Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 23

Trial Status

Completed1
Other2

Role Distribution

Principal Investigator3
PI Rate100%

Activity Timeline

Clinical Trials (3)

NCT06463457Phase 2Active Not Recruiting
Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)
Advanced Prostate CancerHormone Sensitive Prostate CancerProstate Cancer
PrincipalinvestigatorStart date: 2024-12-13
NCT04751929Phase 2Completed
Abemaciclib With or Without Atezolizumab for mCRPC
Metastatic Castration-resistant Prostate CancerProstate Cancer
PrincipalinvestigatorStart date: 2021-08-20
NCT07592910Phase 2Not Yet Recruiting
A Study of Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor Therapy
Metastatic Castrate Resistant Prostate Cancer (mCRPC)Prostate Cancer (Adenocarcinoma)
Principalinvestigator

Research Network

Collaboration Network

2 collaborators·1 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Michael Schweizer, MD

University of Washington- Fred Hutch Cancer Center

Related
1 trials

Shared therapeutic areas:

Metastatic Castrate Resistant Prostate Cancer (mCRPC)Prostate Cancer (Adenocarcinoma)

Worked with same sponsors:

Dana-Farber Cancer InstituteFred Hutchinson Cancer Center+2 more
Collaborated on 1 trial
Similarity Score24%

Zhaohui Zhu, MD

Peking Union Medical College Hospital

Related
19 trials

Shared therapeutic areas:

Prostate CancerMetastatic Castration-resistant Prostate Cancer
Similarity Score10%

Rahul Aggarwal, MD

University of California, San Francisco

Related
22 trials

Shared therapeutic areas:

Prostate CancerMetastatic Castration-resistant Prostate Cancer
Similarity Score10%

James L Gulley, M.D.

National Cancer Institute (NCI)

Related
18 trials

Shared therapeutic areas:

Prostate CancerMetastatic Castration-resistant Prostate Cancer
Similarity Score10%

Kevin Volpp, MD, PhD

University of Pennsylvania

Related
12 trials

Shared therapeutic areas:

Prostate Cancer
Similarity Score5%

Dong-Xin Wang, MD, PhD

Peking University First Hospital

Related
74 trials

Shared therapeutic areas:

Prostate Cancer
Similarity Score5%

Neha sharma, PhD

Warwick Research Services

Related
11 trials

Shared therapeutic areas:

Prostate Cancer
Similarity Score5%

Stanislaw R. Burzynski, MD, PhD

Burzynski Research Institute

Related
62 trials

Shared therapeutic areas:

Prostate Cancer
Similarity Score5%

Barbara Murphy, MD

Vanderbilt-Ingram Cancer Center

Related
14 trials

Shared therapeutic areas:

Prostate Cancer
Similarity Score5%

Charles L. Loprinzi, MD

Mayo Clinic

Related
14 trials

Shared therapeutic areas:

Prostate Cancer
Similarity Score5%

Publications (0)

No publications found for this investigator.

Clinical Trials (3)

Showing 3 of 3 trials

NCT06463457Phase 2PrincipalInvestigator

Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)

Advanced Prostate CancerHormone Sensitive Prostate CancerProstate Cancer
Active Not Recruiting
NCT04751929Phase 2PrincipalInvestigator

Abemaciclib With or Without Atezolizumab for mCRPC

Metastatic Castration-resistant Prostate CancerProstate Cancer
Completed
NCT07592910Phase 2PrincipalInvestigator

A Study of Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor Therapy

Metastatic Castrate Resistant Prostate Cancer (mCRPC)Prostate Cancer (Adenocarcinoma)
Not Yet Recruiting

All 3 trials loaded